A Phase II Study of UCN-01 in Combination With Topotecan in Patients With SCLC Who Relapsed or Progressed greater than or equal to 3 Months After Completing First-Line Platinum-Based Chemotherapy

Trial Profile

A Phase II Study of UCN-01 in Combination With Topotecan in Patients With SCLC Who Relapsed or Progressed greater than or equal to 3 Months After Completing First-Line Platinum-Based Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2015

At a glance

  • Drugs Topotecan (Primary) ; UCN 01 (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 22 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 22 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top